In the News
Servier Doubles Up on Digital Twin Alliance with Aitia
French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.
Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect”…
UCB Enters Drug Discovery Collaboration with Aitia
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder…
Research Identifies Potential New Biomarkers of Atherosclerotic Coronary Artery Disease
This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data…
Becoming Aitia: Why GNS Shifted from AI Provider to Drug Discoverer
CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners…
New Biomarkers for Atherosclerosis Found Using Digital Twins
Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology…
The Milken Institute Future of Health Summit – “Is AI Just What the Doctor-or Patient-Ordered?” Panel Discussion
Watch now the panel titled “Is AI Just What the Doctor-or Patient-Ordered?” with our own Colin Hill joined by the estimated panelists at the Milken Institute Future of Health Summit 2022
Intelligent Technology Brings Companies To A New Moment Of Truth
GNS Healthcare used its causal AI platform to not only predict which patients with metastatic colorectal cancer will respond to which treatments, but why…
Colin Hill Opening Keynote at the Annual Merck Technology Symposium 2022
Our CEO, Colin Hill gave an opening keynote entitled “Can Virtual Patients Unlock The Biological Complexity Of Human Disease And Drive the Next Wave Of Breakthrough Drugs?” in this year annual Merck technology symposium…
How AI is helping “drug hunters” succeed – GNS Co-founder, Iya Khalil talk on CNN
GNS Co-Founder Iya Khalil weighed in on how using AI and big data will transform medicine.